linjc16/ctgov huggingface dataset:
Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders

Study Overview
=================
Brief Summary
-----------------
In this protocol, a combination of MRI, blood, and cerebrospinal fluid (CSF) analysis will be used to understand the natural history, underlying immunologic mechanisms, and clinical implications of central nervous system (CNS) lesions, in particular lesions in the cerebral cortex, in multiple sclerosis (MS) and other inflammatory and autoimmune disorders affecting the CNS. Patients with these disorders, as well as healthy controls, will undergo baseline clinical evaluation and testing, bloodwork, and MRI, with follow up clinical evaluation, bloodwork, and MRI at years 1, 3, and 6. Additional MRIs may be performed in patients with possible new lesion formation or to compare MRI techniques. Lumbar puncture will be performed on participants who are not currently being treated with disease modifying therapies and who are willing to undergo the procedure.

Official Title
-----------------
Longitudinal Investigation of Cortical Demyelination and Meningeal Inflammation in Multiple Sclerosis and Related Disorders

Conditions
-----------------
Multiple Sclerosis, Neuromyelitis Optica, Demyelinating Autoimmune Diseases, CNS

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years old able to provide consent in English able to undergo MRI Exclusion Criteria: contraindication to MRI pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MS Participant<br>Adults with multiple sclerosis | |
| Control Participant<br>Adults without neurologic disease | |
| Other Neuroinflammatory Participants<br>Adults with a neuroinflammatory disease that is not multiple sclerosis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cortical Lesion Number | Lesions in the cerebral cortex | at 6 years (end of study) |
The NORwegian Atrial Fibrillation Self-SCREENing

Study Overview
=================
Brief Summary
-----------------
Atrial fibrillation (AF) is common, increases the risk of mortality, stroke and heart failure, and portending significant burden to patients, societal health and health economy. One of three AF cases are undiagnosed. Several methods for detection of AF exist, but most of them have major limitations and are associated with resource-demanding diagnostic workup in the speciality health care services. This randomized clinical trial will evaluate whether self-screening for AF with the ECG247 patch monitor will reduce AF-related morbidity.

Official Title
-----------------
The NORwegian Atrial Fibrillation Self-SCREENing

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Diagnostic Test: Long-term continuous ECG monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥65 years and minimum one other risk factor for stroke according to the CHA2DS2-VASc risk score: Age ≥75 years, Diabetes, Heart failure, Hypertension, Previous stroke/TIA and/or Vascular disease Informed consent for participation Exclusion Criteria: History of AF (self-reported) Use of anticoagulation therapy Pacemaker/CRT device No smart phone

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ECG screening<br> | Diagnostic Test: Long-term continuous ECG monitoring<br>* Long-term continuous ECG monitoring with ECG247 Smart Heart Sensor<br>|
| No Intervention: No ECG screening<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stroke | all-cause | 5 years |
Studying the Clinical Trial Experiences of Patients With Mesothelioma

Study Overview
=================
Brief Summary
-----------------
Medical research participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical study may make it more difficult for patients to take part or see it through. The data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future mesothelioma patients during clinical trials.

Official Title
-----------------
Mesothelioma Clinical Trials Review: Examining Patient Experiences in Mesothelioma Clinical Trials to Identify Influencing Factors

Conditions
-----------------
Mesothelioma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have a medical diagnosis of mesothelioma that has been confirmed by a physician. Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed. Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study. Exclusion Criteria: Pregnant or lactating woman Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent. Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or interfere with the interpretation of safety results

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a mesothelioma medical study. |  | 3 months | 
| Number of mesothelioma patients who remain in clinical trial until completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mesothelioma
Retrospective Analysis for Patients With Metabolic Syndrome

Study Overview
=================
Brief Summary
-----------------
The incidence of metabolic syndrome and related diseases is gradually increasing, and diet and medication are currently common outpatient treatment methods. This study retrospectively analyzes the clinical data of patients with metabolic syndrome and related diseases who have visited our outpatient department in the past 10 years, compares the therapeutic effects of different treatment methods on their blood glucose, blood lipids, blood pressure, uric acid, and body composition, and provides evidence support for clinical treatment.

Official Title
-----------------
Retrospective Analysis of Outpatient Intervention Effects in Patients With Metabolic Syndrome

Conditions
-----------------
Metabolic Syndrome

Intervention / Treatment
-----------------
* Other: dietary, semaglutide or/and metformin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • individuals who had at least a 2 follow up visits with a BMI of 24 or more with the pri-mary goal of losing weight. Exclusion Criteria: patients did not follow-up on a monthly basis; patients followed-up less than 1 times within 3 months; patients having incomplete data; patients changing their interventions during fol-low-ups

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| low-carbohydrate diet<br>20-30% carbohydrates, 40-45%fat, and 30-40%protein | Other: dietary, semaglutide or/and metformin<br>* patients were prescribed dietary and pharmaceuticals for weight loss<br>|
| balanced diet<br>50-65% carbohydrate, 20-30% fat and 10-20% protein | Other: dietary, semaglutide or/and metformin<br>* patients were prescribed dietary and pharmaceuticals for weight loss<br>|
| pharmacotherapy<br>semaglutide (1mg per week) or/and metformin (o.5g three times a day) | Other: dietary, semaglutide or/and metformin<br>* patients were prescribed dietary and pharmaceuticals for weight loss<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| weight | Weight was measured through multi-frequency bioelectrical impedance analysis InBody 720 (Bio Space Co., Seoul, Korea) at various time points | 0month/1month/2months/3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visceral fat area(VFA) | VFA was measured through multi-frequency bioelectrical impedance analysis InBody 720 (Bio Space Co., Seoul, Korea) at various time points | 0month/1month/2months/3 months | 
| skeletal muscle mass(SMM) | SMM was measured through multi-frequency bioelectrical impedance analysis InBody 720 (Bio Space Co., Seoul, Korea) at various time points | 0month/1month/2months/3 months |
Ultrasound Guided Median Nerve Hydrodissection Using Dextrose

Study Overview
=================
Brief Summary
-----------------
to compare the efficacy of dextrose 5% with steroid hydrodissection in patients with carpal tunnel syndrome

Detailed Description
-----------------
in some cases there is prohibition to use steroid with example the patient rejection to use steroid the maneuver planned median nerve hydrodissection using ultrasound and 10 mld of dextrose 5%, unleash the median nerve for the surrounding structure and short follow up planned to be 2 weeks

Official Title
-----------------
Efficacy of Dextrose 5% in Comparison With Steroid in Median Nerve Ultrasound Guided Hydrodissection in Patients With Carpal Tunnel Syndrome

Conditions
-----------------
Carpal Tunnel Syndrome

Intervention / Treatment
-----------------
* Procedure: dextrose 5% median nerve hydrodissection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: severe carpal tunnel syndrome failed medical management - Exclusion Criteria: previous failed surgery previous failed injection previous failed trial of hydrodissection cervical or brachial nerve entrapment wrist osteoarthritis or rheumatoid pregnant diabetes mellitus -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: 2 groups comparing the efficacy of dextrose water 5 % in median nerve hydrodissection
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: dextrose 5%<br>10 mls of dextrose under ultrasound to separate the median nerve from adjacent structures | Procedure: dextrose 5% median nerve hydrodissection<br>* planned to be a good alternative to steroid hydrodissection<br>|
| Active Comparator: steroid<br>10 mls of steroid used to separate the median nerve from adjacent structures | Procedure: dextrose 5% median nerve hydrodissection<br>* planned to be a good alternative to steroid hydrodissection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain relief in 2 weeks follow up | difference in sensory and functional symptoms post median nerve hydrodissection using dextrose and compare this effect with steroid population arm using Boston questionnaire | 6 months |
Anti-mullerian Hormone in Acute Lymphoblastic Leukemia

Study Overview
=================
Brief Summary
-----------------
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with current survival rates exceeding 90%. As cure rates improve, increasing attention is focused on survivor quality of life, including fertility. It is generally accepted that cancer treatments in childhood may interfere with gonadal function, reducing the pool of primordial follicles and consequently causing premature menopause in women. Anti-Mullerian hormone (AMH) levels is a valuable quantitative indicator of ovarian reserve, being directly related to the number of antral follicles. The evaluation of this hormone makes it possible to identify women at risk of early menopause and to propose them interventions for monitoring and preservation of oocytes, allowing girls to be able to have children once they reach adulthood. The objective of this study is to determine ovarian reserve in girls with ALL before and after treatment by means of the evaluation of the AMH assay.

Official Title
-----------------
Anti-mullerian Hormone in Pediatric Patients Treated for Acute Lymphoblastic Leukemia

Conditions
-----------------
Acute Lymphoblastic Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female less than 18 years of age Diagnosis of acute lymphoblastic leukemia enrollment within the first month after diagnosis Exclusion Criteria: Previous treatments with cytostatics drugs ALL as a second malignancy Syndromic patient or primary hypogonadism

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of blood AMH levels before ALL treatment | AMH levels will be evaluated in peripheral blood | Within one months from ALL diagnosis | 
| Evaluation of blood AMH levels after ALL treatment | AMH levels will be evaluated in peripheral blood | 24 months after ALL diagnosis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fertility preservation, Acute Lymphoblastic Leukemia, Anti-Mullerian hormone
Peroperative Effect of Regional Anesthesia in Hip Surgery

Study Overview
=================
Brief Summary
-----------------
A total of 120 patients scheduled for surgical operation due to hip fracture were divided into two randomized groups. The first group received pericapsular nerve group (PENG) block, while the second group received lumbar erector spinae plane (L-ESP) block prior to the surgery. Subsequently, all patients were positioned in the lateral decubitus position before spinal anesthesia and compared in terms of anesthesia effectiveness through pain scores.

Official Title
-----------------
Comparison of the Peroperative Efficacy of Pericapsular Nerve Group Block and Lumbar Erector Spina Plan Block Applied Preoperatively in Patients Undergoing Hip Fracture Operation

Conditions
-----------------
Analgesia

Intervention / Treatment
-----------------
* Procedure: Pericapsular Nerve Group Block
* Procedure: Lumber Erector Spinae Plane Block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - American Society of Anesthesiologists(ASA) 2-3 patients undergoing surgery due to hip fracture. Exclusion Criteria: Patients in whom regional anesthesia is contraindicated. Patients who are unable to communicate. Patients with a known allergy to local anesthetics. Patients with organ failure.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: PENG block group<br> | Procedure: Pericapsular Nerve Group Block<br>* 1st group to be applied PENG block<br>|
| Experimental: L-ESP group<br> | Procedure: Lumber Erector Spinae Plane Block<br>* 2nd group to be applied Lumber ESP block<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analgesia | Pain measurement via Visual Analog Scale (VAS) scores | 30 minutes |
68Ga-labeled NY105 PET Imaging in Patients

Study Overview
=================
Brief Summary
-----------------
This is a single arm study to evaluate the safety and biodistribution of 68Ga-labeled NY105 PET Imaging in patients

Official Title
-----------------
68Ga-labeled NY105 PET Imaging in Patients

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Drug: 68Ga-NY105


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients voluntarily signed informed consent; Age 18-75, male or female; Patients diagnosed with cancer confirmed by histopathology or cytology; At least one measurable solid lesion has been examined according RECIST1.1 standard; ECOG score 0 3. Exclusion Criteria: Recovery from major trauma (including surgery) within 4 weeks prior to study treatment; Patients with systemic or locally severe infections, or other serious coexisting diseases; Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines; Patients with autoimmune diseases, including rheumatoid arthritis; Inadequate control of arrhythmias, including atrial fibrillation; Uncontrolled hypertension; Patients with allergies or allergies to any component of the imaging agent or antibody; Patients who cannot undergo PET/CT imaging scan; Syphilis, HBV, HCV, or HIV positive subjects; Male and female subjects of reproductive age cannot take effective contraceptive measures; Pregnant or lactating women; Patients with a history of mental illness or related conditions; Other subjects considered unsuitable by researchers.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 68Ga-NY105<br> | Drug: 68Ga-NY105<br>* Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY105<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of tissue distribution of 68Ga-NY105 | Biodistribution of 68Ga-NY105 evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs during repeated 68Ga-PET scans will be reported. | 1 day |
Comparison Of Coughing and Active Cycle of Breathing Technique to Improve Pulmonary Functions in Post-Surgical Patients

Study Overview
=================
Brief Summary
-----------------
To find out the Comparison Of Coughing and Active Cycle of Breathing Technique to Improve Pulmonary Functions in Post-Surgical Patients

Official Title
-----------------
Comparison Of Coughing and Active Cycle of Breathing Technique to Improve Pulmonary Functions in Post-Surgical Patients

Conditions
-----------------
Post Surgical

Intervention / Treatment
-----------------
* Behavioral: Active Cycle of Breathing
* Diagnostic Test: Coughing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both male and female between the age of 18-50 years who reported post-surgical complications related to pulmonary will be selected in this study Exclusion Criteria: If patient is unresponsive, psychologically disturbed and does not want to participate, teenagers will be excluded from this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Coughing<br> | Diagnostic Test: Coughing<br>* Coughing to Improve Pulmonary Functions in Post-Surgical Patients<br>|
| Experimental: Active Cycle of Breathing<br> | Behavioral: Active Cycle of Breathing<br>* Active Cycle of Breathing Technique to Improve Pulmonary Functions in Post-Surgical Patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Spirometry-related questions |  | 6 Months | 
| surgical Related Questioner |  | 6 Months |